Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes.
Two biodegradable cationic lipids, stearylamine and DC-Chol, were chosen to investigate the effect of cationic lipids on the in vitro and in vivo characteristics of hydrophilic proteins or peptides of low isoelectric point. Thrombin inhibitor recombinant hirudin variant-2 (rHV2) was selected as the model drug. The cationic lipids were found to achieve higher entrapment efficiency of rHV2 in liposomes than zwitterionic lipids. The positively charged liposomes became less positive and relatively stable in serum after loading rHV2. The cationic liposomes induced sustained release of rHV2 in the presence of plasma, significantly prolonged the antithrombotic efficacy and plasma level of rHV2 after intravenous injection in rats in comparison with neutral lipid liposomes, especially for stearylamine group. Both clotting times correlated well with plasma rHV2 levels. No serious adverse events were observed and physical state of rats was satisfactory for all the formulations. Electrostatic interaction between negative charge of rHV2 and cationic liposomes was confirmed and it might affect all the characteristics of rHV2 loaded cationic vehicles. The findings suggest that cationic liposomes may be a potential sustained-release delivery system for parenteral administration of hydrophilic proteins or peptides with low isoelectric point to prolong efficacy and improve bioavailability.
Meng
Meng
M
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100083, PR China.
Liu
Yu
Y
Wang
Yi-Bo
YB
Wang
Jian-Cheng
JC
Zhang
Hua
H
Wang
Xue-Qing
XQ
Zhang
Xuan
X
Lu
Wan-Liang
WL
Zhang
Qiang
Q
D000588:Amines / Q000737:chemistry; D000818:Animals; D001682:Biological Availability; D001777:Blood Coagulation / Q000187:drug effects; D002412:Cations; D002784:Cholesterol / Q000031:analogs & derivatives / Q000737:chemistry; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D006629:Hirudins / Q000235:genetics / Q000493:pharmacokinetics / Q000494:pharmacology*; D007263:Infusions, Parenteral; D054709:Lecithins / Q000737:chemistry; D008297:Male; D010314:Partial Thromboplastin Time; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D055672:Static Electricity; D013918:Thrombin Time; D053835:Unilamellar Liposomes / Q000138:chemical synthesis / Q000737:chemistry*
D000588:Amines; D002412:Cations; D005343:Fibrinolytic Agents; D006629:Hirudins; D054709:Lecithins; D011994:Recombinant Proteins; D053835:Unilamellar Liposomes; C072299:hirudin HV2; C070648:3-(N-(N',N'-dimethylaminoethane)carbamoyl)cholesterol; D002784:Cholesterol; C009317:stearylamine